Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “obinutuzumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 14
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 14 pipeline programs matching "obinutuzumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

14 results for “obinutuzumab” Back to intelligence hub

Search results

  1. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial
  2. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial
  3. Obinutuzumab

    United Therapeutics Europe Ltd

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial
  4. obinutuzumab

    Hoffmann-La Roche

    Lymphocytic Leukemia, Chronic

    phase 3 small molecule completed

    1 trial
  5. Induction therapy of GP(Pomalidomide+Obinutuzumab)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial
  6. Linperlisib combination with obinutuzumab

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 2 small molecule active

    1 trial
  7. OBINUTUZUMAB, Zanubrutinib

    BeiGene

    Relapsed/Refractory Follicular Lymphoma

    phase 2 small molecule active

    1 trial
  8. Obinutuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial
  9. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial
  10. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial
  11. Obinutuzumab Injection [Gazyva]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials
  12. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial
  13. FL-ZBG-01

    The First People's Hospital of Lianyungang

    Follicular Lymphoma

    small molecule active

    1 trial
  14. Obinutuzumab

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.